Table 3.

Changes in the SIRT1, SIRT3, SIR6, and ROS values before and after treatment.

		Saline control group (n = 29)	NAD+ group (n = 29)	F	p-value
SIRT1
	Baseline SIRT1, ng/mL ($\overline{x}$ $\pm$ s)	2.28 $\pm$ 0.47	1.78 $\pm$ 0.39
	2WK-SIRT1, ng/mL ($\overline{x}$ $\pm$ s)	1.98 $\pm$ 0.43	2.37 $\pm$ 0.36
	4WK-SIRT1, ng/mL ($\overline{x}$ $\pm$ s)	1.91 $\pm$ 0.50	2.01 $\pm$ 0.43
	12WK-SIRT1, ng/mL ($\overline{x}$ $\pm$ s)	1.57 $\pm$ 0.18	1.99 $\pm$ 0.35
	Time			4.620	0.005
	Group			1.285	0.269
	Group*time			7.440	0.000
SIRT3
	Baseline SIRT3, ng/mL ($\overline{x}$ $\pm$ s)	3.66 $\pm$ 0.74	3.35 $\pm$ 0.41
	2WK-SIRT3, ng/mL ($\overline{x}$ $\pm$ s)	3.63 $\pm$ 0.66	3.52 $\pm$ 1.47
	4WK-SIRT3, ng/mL ($\overline{x}$ $\pm$ s)	3.30 $\pm$ 0.56	3.89 $\pm$ 0.88
	12WK-SIRT3, ng/mL ($\overline{x}$ $\pm$ s)	3.49 $\pm$ 0.18	3.64 $\pm$ 0.39
	Time			0.076	0.923
	Group			0.212	0.650
	Group*time			1.950	0.156
SIRT6
	Baseline SIRT6, ng/mL ($\overline{x}$ $\pm$ s)	3.05 $\pm$ 0.98	3.52 $\pm$ 0.62
	2WK-SIRT6, ng/mL ($\overline{x}$ $\pm$ s)	3.15 $\pm$ 0.92	3.85 $\pm$ 1.24
	4WK-SIRT6, ng/mL ($\overline{x}$ $\pm$ s)	3.18 $\pm$ 0.63	3.35 $\pm$ 0.81
	12WK-SIRT6, ng/mL ($\overline{x}$ $\pm$ s)	3.00 $\pm$ 0.40	2.98 $\pm$ 0.46
	Time			1.470	0.239
	Group			6.168	0.021
	Group*time			0.825	0.458
ROS
	Baseline ROS, ng/mL ($\overline{x}$ $\pm$ s)	5.71 $\pm$ 1.24	5.35 $\pm$ 1.30
	2WK-ROS, ng/mL ($\overline{x}$ $\pm$ s)	5.20 $\pm$ 1.06	5.69 $\pm$ 1.30
	4WK-ROS, ng/mL ($\overline{x}$ $\pm$ s)	4.76 $\pm$ 0.69	4.99 $\pm$ 1.18
	12WK-ROS, ng/mL ($\overline{x}$ $\pm$ s)	4.54 $\pm$ 0.52	4.75 $\pm$ 0.96
	Time			4.260	0.008
	Group			0.380	0.544
	Group*time			0.741	0.531

p-values delineate comparisons of SIRT1, SIRT3, and ROS between the two groups over the three follow-up visits and are based on statistical methods using Fisher’s exact test. SIRT1, sirtuin-1; SIRT3, sirtuin-3; SIRT6, sirtuin-6; ROS, reactive oxygen species; NAD⁺, nicotinamide adenine dinucleotide; 2WK, 2-week follow-up; 4WK, 4-week follow-up; 12WK, 12-week follow-up.